#1Roche#2Roche This presentation contains certain forward-looking statements. These forward-looking statements may be identified by words such as 'believes', 'expects', 'anticipates', 'projects', 'intends', 'should', 'seeks', ‘estimates', 'future' or similar expressions or by discussion of, among other things, strategy, goals, plans or intentions. Various factors may cause actual results to differ materially in the future from those reflected in forward-looking statements contained in this presentation, among others: 1 pricing and product initiatives of competitors; 2 legislative and regulatory developments and economic conditions; 3 delay or inability in obtaining regulatory approvals or bringing products to market; 4 fluctuations in currency exchange rates and general financial market conditions; 5 uncertainties in the discovery, development or marketing of new products or new uses of existing products, including without limitation negative results of clinical trials or research projects, unexpected side-effects of pipeline or marketed products; 6 increased government pricing pressures; 7 interruptions in production; 8 loss of or inability to obtain adequate protection for intellectual property rights; 9 litigation; 10 loss of key executives or other employees; and 11 adverse publicity and news coverage. Any statements regarding earnings per share growth is not a profit forecast and should not be interpreted to mean that Roche's earnings or earnings per share for this year or any subsequent period will necessarily match or exceed the historical published earnings or earnings per share of Roche. For marketed products discussed in this presentation, please see full prescribing information on our website www.roche.com All mentioned trademarks are legally protected.#3Roche 2022 results Basel, 2 February 2023 Roche#4Group Severin Schwan Chief Executive Officer Roche#52022 performance Outlook Roche#62022: Good Group results Group sales +2% driven by good performance in both divisions • . • Pharma portfolio rejuvenation ongoing, key products offsetting LOE impact Diagnostics with good growth momentum driven by strong base business (+7%) Decline of roughly CHF 1 bn in COVID-19 sales Profit and Cash Flow • Core EPS growth +5%, Operating Free Cash Flow remains strong (CHF 17.7bn) Roche Growth supported by key products and strong launches • . • Pharma key products Ocrevus, Hemlibra, Vabysmo, Evrysdi, Tecentriq, Phesgo and Polivy continuing to grow strongly Key approvals achieved: Vabysmo in nAMD/DME in US/EU; Polivy in 1L DLBCL in EU/Japan/China; Tecentriq in adjuvant NSCLC in EU; Lunsumio in 3L+FL in US/EU Launches of next generation of SARS-CoV-2 rapid antigen test 2.0, cobas® HCV DUO, Elecsys® pTau/AB42 ratio Gen2 CSF (FDA). Benchmark Ultraplus, Digital LightCyler, cobasⓇ pure and 5800 (FDA) Significant newsflow in 2023 • • Pharma: 16 late-stage read-outs incl. 3 NMEs (tiragolumab, crovalimab, SRP-9001) and important line extensions for Tecentriq, Venclexta, Alecensa, Ocrevus, Lunsumio and TNKase; positive results for Tecentriq in adjuvant HCC and Susvimo in DME/DR achieved Diagnostics: CCM Vertical, LightCycler Pro, Anti-HEV IgG/IgM, HBeAg Quant, IL-6 Neonatal sepsis Growth rates at CER (Constant exchange Rates); LOE-loss-of-exclusivity 6#72022: Guidance achieved Targets for 2022 Group sales growth1 Stable- to low-single digit FY 2022 +2% Core EPS growth1 Low- to mid-single digit +5% Dividend outlook Further increase dividend in Swiss francs² CHF 9.50 1 At constant exchange rates (CER); 2 2022 dividend as proposed by the Board of Directors Roche 7#82022: Good sales growth in both divisions despite COVID-19 headwinds 2022 2021 Change in % CHFbn CHFbn CHF CER Pharmaceuticals Division 45.6 45.0 1 2 Diagnostics Division 17.7 17.8 0 3 Roche Group 63.3 62.8 1 2 CER=Constant Exchange Rates; totals may include differences due to rounding Roche 8#9Quarterly sales performance: COVID-19 sales declining 15% 13% 14%* 12% 11% 9% 9% 10% 7% 7% 7% 6% 6% 6% 6% 6% 8% 8% 4% 5% 4% 7% 6% 5% 5% 4% 4% 1% 3% 3% 3% 0% 1% 0% -5% -10% -15% AHR¹ impact -4% COVID-19 impact -6% Q1 Q2 Q3 Q4 Q1 Q2 Q3 Q4 Q1 Q2 Q3 Q4 Q1 Q2 Q3 Q4 Q1 Q2 Q3 Q4 Q1 Q2 Q3 Q4 Q1 Q2 Q3 Q4 Q1 Q2 Q3 Q4 15 15 15 15 16 16 16 16 17 17 17 17 18 18 18 18 19 19 19 19 20 20 20 20 21 21 21 21 22 22 22 22 Growth rates at CER (Constant Exchange Rates); * Q2 2020 sales severely impacted by COVID-19 pandemic onset; 1AHR: Avastin, Herceptin, Rituxan/MabThera Roche 9#102022: Pharma and Diagnostics underlying business driving growth CHFM 62'801 +2% at CER Diversification of Roche business +273 +903 +3'356 -801 -1,883 2017 CHF 53.3bn -457 -911 Total COVID-19 sales decline equals roughly 1bn 63'281 AHR Diagnostics Other pharma Ophthalmology 2022 CHF 63.3bn AHR Roche Oncology Immunology Neuroscience 2021 Dia Dia Pharma Ronapreve Actemra base COVID-19 excl. sales business sales Ronapreve, Actemra, AHR sales AHR erosion1 Fx 2022 Infectious diseases Hemophilia A 2022 values in reported CHFm, variances in CERm; 1AHR: Avastin, Herceptin, Rituxan/MabThera sales erosion 10 10#11Pharma portfolio rejuvenation ongoing 16 blockbusters at the end of 2022, compared to 8 in 2015 TECENTRIQ™ atezolizumab VENCLEXTA venetoclax tablets 100 LUXTURNA voretigene neparvovec-rzyl subretinal injection xofluza (balaavir marbeniables HEMLIBRA. emicizumab-kxwh 50 SALECENSA™ alectinib capsules OCREVUS ocrelizumab ×COTELLIC POLIVY polatuzumab vedotin ENSPRYNG ROZLYTREK PHESGO pertuzumab trastuzumabund SUBCUTANE BUSINE CHFM 20,000 SuSvim o™ Evrysdi. ranibizumab injection 15,000 risdiplam GAVRETO praisetino 24% VABYSMO Lunsumic 10,000 RONAPREVE casirivimab and indevimab mosunetuzumab 16% 2016 2017 2018 | 2019 2020 2021 2022 2023 Expected NME launches:** ⚫ glofitamab SRP-9001 crovalimab 5,000 35% Roche % of Pharma Sales* 44% 0 FY 2019 FY 2020 Cotellic Hemlibra Alecensa Xofluza FY 2021 Tecentriq FY 2022 Ocrevus Polivy Rozlytrek Phesgo Enspryng Evrysdi Gavreto Ronapreve Susvimo Vabysmo Lunsumio * Venclexta sales booked by AbbVie and therefore not included, ** SRP-9001: Accelerated US-filing by partner company Sarepta; crovalimab: First filing in China 11#122022: Underlying business with strong momentum at year-end % CER Pharma Quarterly sales evolution 2021-2022 % CER Diagnostics Quarterly sales evolution 2021-2022 +55% +55% +48% +55% +45% +45% +35% +35% +31% +24% +25% +25% +17% +18% +14% +15% +15% +9% +9% +8% +7% +4% +5% +6% +6% +3% +5% +2% +5% +11% +7% +5% +8% +10% -5% -9% +2% 0% -5% 0% -1% -3% -6% -4% -13% -9% -15% -15% Q1 Q2 Q3 Q4 Q1 Q2 Q3 Q4 Q1 Q2 Q3 Q4 Q1 Q2 Q3 Q4 2021 vs. 2020 2022 vs. 2021 2021 vs. 2020 2022 vs. 2021 -Pharma Pharma Underlying business' Diagnostics Diagnostics Base business Growth rates at CER (Constant Exchange Rates); 1 Excl. Ronapreve and total Actemra Roche 12#132022: EPS growth +5%, operating cash flow remains strong Core operating profit 36.9% % of sales 34.9% 35.0% +3% at CER 22.2 CHFbn CHF 21.5 21.9 Core EPS Operating free cash flow +5% at CER CHFbn 20.30 19.81 19.16 30.9% 27.9% 25.4% 14.8 -8% at CER 17.7 19.4 Roche 2020 2021 2022 2020 2021 2022 2020 2021 2022 CER-Constant Exchange Rates 13#142022: 36th consecutive annual dividend increase CHF 10 9 80 7 65 4 3 2 1 0 1989 1994 1999 CAGR = 12.9% 2004 2009 2022 dividend as proposed by the Board of Directors; Note: For 1995, a special dividend was paid out to mark F. Hoffmann-La Roche's 100th anniversary in 1996 Roche 9.50 2014 2019 14#152022 performance Outlook Roche#162023: Upcoming newsflow Pharma Tiragolumab + Tecentriq in 1L PDL 1+ NSCLC Tiragolumab + Tecentriq + chemo in 1L Esophageal Tecentriq + Avastin in adjuvant HCC Tecentriq in adjuvant SCCHN Tecentriq+chemo in adjuvant TNBC Tecentriq neoadjuvant/adjuvant TNBC Phesgo OBI in HER2+ BC Alecensa in adjuvant ALK+ NSCLC Venclexta + azacitidine in 1L high risk MDS Venclexta + dexamethasone in R/R MM (t11;14) Glofitamab + GemOx in 2L+ DLBCL Lunsumio + Polivy in 2L+ DLBCL* Crovalimab in PNH Delandistrogene moxeparvovec (SRP-9001) in DMD Ocrevus 6m SC in RMS / PPMS TNKase in Stroke Susvimo in DME Susvimo in DR Xolair in Food allergy Neuroscience Ophthalmology Oncology/Hematology Immunology Diagnostics Roche CCM Vertical LightCycler Pro Anti-HEV IgG and Anti-HEV IgM HBeAg Quant IL-6 Neonatal sepsis (claim extension) Diagnostics Modular transportation system, integrated into existing cobas connection modules Flexible real-time PCR instrument with dual IVD and Research mode Anti-HEV IgM: Immunoassay aiding in diagnosis of acute HEV infection in clinic. Anti-HEV IgG: Immunoassay aiding in detection of a recent or past HEV infection Immunoassay aiding in diagnosis, monitoring and predicting treatment response for patients with hepatitis B Immunoassay with dedicated claim aiding in diagnosis of sepsis in neonates DME-diabetic macular edema; DLBCL-diffuse large B-cell lymphoma; NSCLC=-non-small cell lung cancer; HCC-hepatocellular carcinoma; MM-multiple myeloma; RVO-retinal vein occlusion; CSF-cerebrospinal fluid; PCR-polymerase chain reaction; SC=subcutaneous; DR-diabetic retinopathy; RMS=relapsing MS; PPMS-primary progressive MS; PNH=Paroxysmal nocturnal hemoglobinuria; TNBC-triple negative breast cancer; SCCHN-squamous cell carcinoma of head and neck; DMD-Duchenne muscular dystrophy; *Results are event-driven, read-outs expected 2023/24; OBI-on-body injector 16#172023 sales outlook Sales drivers¹ Pharma: Key products with strong growth and momentum from ongoing launches Diagnostics: Base business with solid growth COVID-19 sales for Diagnostics and Pharma expected to decline by roughly CHF 5bn AHR² sales expected to erode by roughly CHF 1.6bn 1 At Constant Exchange Rates (CER); 2 AHR=Avastin, Herceptin, Rituxan/MabThera Roche Group sales growth¹ Low single digit decline 17#182023 outlook Group sales growth1 • Low single digit decline Core EPS growth¹ Broadly in line with sales decline Dividend outlook • Further increase dividend in Swiss francs 1 At Constant Exchange Rates (CER) Roche 18#19Pharmaceuticals Division Thomas Schinecker CEO Roche Pharmaceuticals Roche#202022: Pharmaceuticals Division sales growth New products compensate for loss-of-exclusivity and COVID-19 sales decline Roche 2022 2021 Change in % CHFM CHFM CHF CER Pharmaceuticals Division 45,551 45,041 1 2 United States 23,322 22,505 4 -1 Europe 8,143 8,876 -8 -2 Japan 4,949 4,506 10 26 International 9,137 9,154 0 1 CER=Constant Exchange Rates 20 20#212022: Pharmaceuticals Division Core OP growth driven by higher gross profit, higher ROOI and lower G&A Roche 2022 CHFm % sales 2022 vs. 2021 CER growth Sales 45,551 100.0 2% Royalties & other op. inc. 3,077 6.8 3% Cost of sales -9,262 -20.3 -2% COGS+PC: -7% M&D -6,657 -14.6 2% R & D -12,096 -26.6 1% G & A -1,441 -3.2 -6% Admin: -2% Core operating profit 19,172 42.1 5% +3% in CHF CER=Constant Exchange Rates; ROOI-royalties and other operating income; COGS=costs of goods sold; PC-period costs 21 21#222022: Portfolio diversification accelerating Currently 16 blockbusters, with Vabysmo and Phesgo emerging Ocrevus Hemlibra Vabysmo Evrysdi Tecentriq Phesgo Ronapreve Polivy Alecensa Perjeta Xolair Kadcyla Enspryng n/a 87% 14% 121% 85% 15% 5% 9% 7% 93% >500% 17% 27% 17% Xofluza Gazyva Tamiflu Esbriet Lucentis -31% -28% Herceptin -19% MabThera -20% Actemra/RoActemra -22% 9% 80% US ■ Europe Japan International Avastin -28% T -1,200 -800 -400 400 800 Absolute values and growth rates at Constant Exchange Rates (CER) 1,200 Roche 22 22#232022: Oncology portfolio Full year sales stable as portfolio rejuvenation progresses HER2 franchise YoY CER growth Phesgo (+121%) • Kadcyla (+7%) with growth ex-US due to adjuvant BC HER2 franchise Herceptin Perjeta (+5%) +3% Kadcyla (+7%) Tecentriq +14% Polivy (+85%) Hematology Rituxan -5% franchise Gazyva (+9%) Avastin -28% Alecensa +15% Cotellic + Cotellic (-3%) -5% Zelboraf Rozlytrek +51% Tarceva -29% Gavreto +175% 0.0 2.0 4.0 6.0 8.0 CHFbn • Perjeta (+5%) driven by International; decline in EU due to conversion Phesgo (CHF 740m): 33% conversion in early launch countries* Tecentriq . Growth (+14%) driven by adjuvant NSCLC, 1L HCC and 1L SCLC Hematology franchise • Venclexta**: Expanding patient share in 1L AML & 1L / R/R CLL . Gazyva (+9%): Growth driven by 1L FL and in 1L CLL Polivy (+85%): Strong 1L DLBCL uptake in early launch countries; Roche • • NCCN guideline inclusion as category 1 granted in Q1 2023 Lunsumio: EU launch in 3L+ FL ongoing; US approval granted in Dec**** NCCN guideline inclusion as category 2A granted in Q1 2023 Alecensa • • Strong growth (+15%) and 1L ALK+ NSCLC leadership in major markets Ph III (ALINA) in adjuvant ALK+ NSCLC expected in 2023 2022 Oncology sales: CHF 20.0bn; CER growth -1%; CER-Constant Exchange Rates; * Phesgo conversion rate is based on volumes (vials) and includes all launch countries after the 2nd quarter after the launch (30 countries); ** Venclexta sales booked by AbbVie and therefore not included; ***Lunsumio launched in the US in Jan 2023; Polivy in collaboration with Seagen; BC=breast cancer; HCC-hepatocellular carcinoma; NSCLC=non-small cell lung cancer; SCLC-small cell lung cancer; AML=acute myeloid leukemia; R/R CLL-relapsed/refractory chronic lymphocytic leukemia; FL-follicular lymphoma; DLBCL-diffuse large B cell lymphoma; NCCN=national comprehensive cancer network; ALK-anaplastic lymphoma kinase 23#24Polivy in 1L DLBCL: First new treatment in >20 years Included in NCCN guideline as category 1*; NICE reimbursement obtained** Ph III (POLARIX) results PFS strongly predicts OS outcomes¹ 100 80 PFS (%) P40 60- 20 3-year APFS: 7.7% HR 0.76 95% CI: 0.60-0.97 0 0 No. of patients at risk Pola-R-CHP R-CHOP PFS Pola-R-CHP (N=440) R-CHOP (N=439) + Censored 12 24 36 48 55 Time (months) 440 439 405 390 354 331 331 300 313 284 242 222 103 94 66 0 0 59 2 1 ASH 2022 A 0.31 n = 25 0.2- r = 0.772 Log HR (OS) 0.1- 0- -0.1- -0.2- -0.3- -0.4+ T -0.4 -0.3 -0.2 -0.1 0 0.1 Log HR (PFS) 0.2 • Updated Ph III (POLARIX) results: median follow-up 39.7 months demonstrated sustained PFS benefit in Pola-R-CHP (HR 0.76) vs. R-CHOP • PFS is a valid endpoint recognized by all major health authorities to demonstrate efficacy benefit in 1L DLBCL • • Polivy in 1L DLBCL has significant potential to decrease cost for progressive disease, due to fewer patients progressing Approved in EU/UK/Japan/China/Canada, overall >50 countries; US filing: ODAC on Mar 9th and PDUFA date set for Apr 2nd Roche POLIVYⓇ polatuzumab vedotin Polivy in collaboration with Seagen; *NCCN guidelines for B-Cell Lymphomas (V1.2023); **NICE: Polatuzumab vedotin in combination for untreated diffuse large B-cell lymphoma [ID3901]; 1 Shi Q, Schmitz N, Ou FS, et al. Progression free survival as a surrogate end point for overall survival in first line diffuse large B cell lymphoma: An individual patient level analysis of multiple randomized trials (SEAL). J Clin Oncol.2018;36(25):2593 2602; DLBCL-diffuse large B-cell lymphoma; PFS=progression free survival; OS-overall survival; R-CH(O)P=Rituxan + cyclophosphamide + doxorubicin + (vincristine) + prednisone; HR-hazard ratio; NCCN=national comprehensive cancer network; NICE=national institute for health and care excellence 24 24#25Lunsumio & glofitamab: Expanding into earlier lines of treatment Off-the-shelf, fixed duration with durable responses and manageable safety Lunsumio Glofitamab Product profile High CR rate and durable responses • Favorable tolerability with low grade CRS • No required hospitalization For outpatient setting, indolent disease (FL) and elderly/unfit patients Regimen Lunsumio Lunsumio + Polivy SUNMO CELESTIMO Roche ASH 2022 Key clinical trials Indication Phl Ph II Ph III 3L+FL US/EU approved 2L+DLBCL (SCT-ineligible) Readout 2023/24 2L+FL IA 2024 r/r CLL Lunsumio 1L DLBCL (elderly/unfit) Lunsumio +Polivy 1L DLBCL (elderly/unfit) Regimen Indication Phl Ph II Ph III Lunsumio+lenalidomide Lunsumio • Best in class efficacy potential, high CR rates and durable responses comparable to CAR-Ts Well tolerated with low rate of discontinuations and ICANS; low grade, predictable CRS glofitamab 3L+ DLBCL glofitamab + GemOx • Minimal CRS in 1L DLBCL combined with R + chemo 2L+ DLBCL (SCT-ineligible) glofitamab+CD19x4-1BBL r/r NHL STARGLO For aggressive disease (1L DLBCL, R/R DLBCL, MCL) glofitamab+CD19xCD28 r/r NHL ASH 2022 Filed in US (PDUFA 1st July) Filed in EU Readout 2023 Glofitamab + Polivy + R-CHP 1L DLBCL Ph III to initiate in 2023 R/R=relapsed refractory; CRS-cytokine release syndrome; FL-follicular lymphoma; DLBCL-diffuse large B-cell lymphoma; CR-complete response; MCL-mantle cell lymphoma; CAR-T-chimeric antigen receptor T cells; ICANS-immune effector cell-associated neurotoxicity syndrome; IA=interim analysis; CLL=chronic lymphocytic leukemia; SCT=stem cell transplantation; NHL-non-Hodgkin's lymphoma; GemOx-gemcitabine oxaliplatin; PDUFA=prescription drug user fee act; R-CHP-rituxan + cyclophosphamide + hydroxydaunorubicin + prednisone 25#26Tecentriq: Further adjuvant read-outs in 2023 First positive read-out in adjuvant HCC; first PD-(L)1 with pivotal SC results filed YoY CER growth +24% CHFM 1,100 1,000 900 +17% 800 +35% 700 +136% 600 500 400 300 200 100 0 Q4 19 Q4 20 Q4 21 Q4 22 US Europe International Japan Q4 update • SC: EU and US filing (PDUFA date set for Sep 15th) Lung franchise (NSCLC, SCLC) • EU: 1L SCLC with continued growth • US: Continued strong launch in adjuvant NSCLC Gl franchise (HCC) • US/EU/Japan: Further growth in 1L HCC Roche • Ph III (IMbrave050) in adjuvant HCC met RFS primary endpoint; OS immature Outlook 2023 • Ph III results in adjuvant SCCHN and TNBC expected; Ph III (IMpower030) in periadjuvant NSCLC continues to 2024 • ⚫ Ph III (SKYSCRAPER-01) Tecentriq + tiragolumab in 1L NSCLC 26 CER=Constant Exchange Rates; SC=subcutaneous; NSCLC-non-small cell lung cancer; HCC-hepatocellular cancer; RFS=recurrence-free survival; SCLC-small cell lung cancer; TNBC=triple-negative breast cancer; SCCHN-squamous cell carcinoma of head and neck; PDUFA-prescription drug user fee act; OS-overall survival#27Hemophilia A: Hemlibra, new global standard of care 36% US/EU-5 patient share reached CHFM 1,200 1,000 800 +45% 600 +313% 400 200 +38% Roche YoY CER growth +24% • Q4 update • >19,000 patients treated globally Hemlibra continues to penetrate across all approved patient segments ⚫ Ph III (HAVEN 7) in infants (0-1 year) interim data presented at ASH 2022 • ⚫ SPK 8011 (hem A gene therapy) 5-year data with stable Factor VIII levels presented at ASH 2022 Outlook 2023 • EU: Label extension to include moderate patients (HAVEN 6) granted in Q1 • • US/EU: Further patient share gains in non-inhibitors • SPK 8011 pivotal Ph III to be initiated 0 Q4 19 Q4 20 Q4 21 Q4 22 US Europe International Japan CER-Constant Exchange Rates 27#28Immunology: Actemra COVID-19 sales declining and Esbriet LOE Xolair autoinjector approval and Ph III food allergy readout expected in 2023 CHFM YoY CER growth 2,500 0% +7% -2% 2,000 -17% 1,500 1,000 500 0 Q4 19 Q4 20 Q421 Rituxan/MabThera (RA) Actemra SC CellCept Esbriet Actemra IV Xolair Pulmozyme Other Q4 22 Q4 updates Actemra (-22%) • • COVID-19 related sales declining Shift from IV to SC ongoing, SC share reaches 60% Xolair (+6%) • Roche Market leader in asthma biologics and strong growth in CSU Esbriet (-48%) • US: Generic competition Outlook 2023 • US approval of Xolair autoinjector expected; Ph III • (OUTMATCH) in food allergy to read out ⚫ Ph III ASO factor B in IgAN to be initiated • ⚫ Ph III (INShore) Gazyva in PNS to be initiated CER=Constant Exchange Rates; LOE-loss of exclusivity; RA=rheumatoid arthritis; IV-intravenous; SC=subcutaneous; CSU-chronic spontaneous urticaria; ASO=antisense oligonucleotide; IgAN-immunoglobulin A nephropathy; PNS=pediatric nephrotic syndrome 28#29Multiple Sclerosis: Global leader, reaching 21% patient share Ph Ill results for 6M SC Ocrevus expected in 2023 Roche CHFM 1,750 1,500 1,250 +55% +10% 1,000 750 500 250 +25% YoY CER growth • +18% Q4 19 Q4 20 Q4 21 Q4 22 ■ US ■ Europe International Q4 update • #1 treatment in US and EU-5, both in total share and new to brand share Higher retention rate than other MS medicines Outlook 2023 • US/EU: Further market share gains expected ⚫ Ph III (OCARINA II) Ocrevus SC with Q6M dosing in RMS & PPMS data read out expected . Ph III (GAVOTTE/MUSETTE) high-dose Ocrevus nearing recruitment completion in Q1 CER=Constant Exchange Rates; MS-multiple sclerosis; SC=subcutaneous; Q6M-every 6 months; RMS=relapsing MS; PPMS-primary progressive MS 29#30Spinal Muscular Atrophy: Evrysdi market leader in US and Japan Switches remain a key source of new patient starts YoY CER growth +59% Q4 update • >7,000 patients treated worldwide; retention rate in first 12 months of ~90% globally US: Growth driven by switch and naive patient starts including patients <2 months old • Ex-US: Continued strong growth and share gains in all major markets CHFM 400 350 300 250 +347% 200 150 100 50 0 Q4 20 Q4 21 Q4 22 . Continued growth and market share gains US Europe International Japan • EU: Label extension (<2 months old) based on Ph II (RAINBOWFISH) expected Outlook 2023 CER-Constant Exchange Rates; SMA-spinal muscular atrophy Roche 30#31SRP-9001 in DMD: Pivotal Ph III results expected at year-end First and potential best-in-class gene therapy Delandistrogene moxeparvovec SAREPTA Roche THERAPEUTICS Clinical trial program overview ITR ssDNA C Promoter Transgene PolyAt 5' 3' OH ITR* Study DMD subgroup Phl Ph II Ph III Comment 101 Ambulatory, 4-7 yrs. US filing by Sarepta Important determinant of 102 expression levels and specificity 10,11 Important determinant of functional impact 10.12 Ambulatory, 4-7 yrs. Delandistrogene moxeparvovec Expression MHCK7 Function Micro-dystrophin Vector H One of the important determinants of safety experience and transduction efficiency Safety AAVrh74 103 (ENDEAVOR) 301 (EMBARK) 302 (ENVOL) 303 (ENVISION) Ambulatory, 3-18 yrs Non-ambulatory, all ages Ambulatory, 4-7 yrs. Ambulatory, 0-3 yrs. US filing by Sarepta US filing by Sarepta* Data read out expected Q4 2023 Ph II to initiate in 2023 Ambulatory, 8-18 yrs Non-ambulatory, all ages Ph III to initiate in 2023 • Targeted delivery of functional shortened dystrophin transgene to muscle tissue Vector and promotor specifically designed for skeletal & cardiac muscles Transgene can enable meaningful and durable response • ● Positive functional and clinically meaningful results at multiple time points (including 1, 2, 4 years after treatment) with consistent safety profile shown for >80 patients US filing by partner Sarepta accepted and priority review granted with PDUFA date set for 29th May ⚫ Ph III (EMBARK) read out expected in Q4; results will form the basis for EU filing . DMD-Duchenne muscular dystrophy; PDUFA-prescription drug user fee act; Delandistrogene moxeparvovec in collaboration with Sarepta Therapeutics; *Cohort 1 only 31#32Ophthalmology: Excellent Vabysmo launch More than 450k vials shipped globally in first 11 months of launch CHFM Q4 update Vabysmo VABYSMO susvim o™ 100mg ml ranibizumab injection Format Roche • US: Strong uptake with switches primarily from aflibercept; use in naive patients further accelerating 350 300 250 200 150 100 50 0 Q122 Q2 22 Q3 22 US Europe International Japan Q4 22 • Rapid launch uptake in UK & Japan • Positive Ph III (BALATON/COMINO) results for Vabysmo in RVO achieved Susvimo • Positive Ph III (PAGODA/PAVILLION) results for Susvimo in DME/DR achieved Outlook 2023 • • Vabysmo: Continued growth and market share gains in nAMD & DME Ph III (MEERKAT/SANDCAT) anti IL-6 mAb in UME started ⚫ Ph Ill results for Vabysmo in RVO and Susvimo in DME/DR to be presented at Angiogenesis (Feb 10-11) DME-diabetic macular edema; RVO-retinal vein occlusion; DR-diabetic retinopathy; UME=uveitic macular edema; mAb-monoclonal antibody; Eylea (aflibercept) is a registered trademark/product of Regeneron 52 32#33VABYSMO Roche Vabysmo: Chosen disease criteria impacts dosing interval Vabysmo nAMD trials use vision or anatomical disease activity criteria, reflecting clinical practice¹ ≥ 5 letters BCVA loss vs avg. BCVA over previous 2 scheduled visits, due to nAMD* Different ≥Q12W disease criteria as applied to TENAYA/LUCERNE patients Stringent criteria (as actually applied in TENAYA/LUCERNE)** Treatment change if ANY criteria are met (based on criteria used in pivotal trials) OR ≥ 10 letters BCVA loss vs highest BCVA recorded over previous 2 scheduled visits, due to nAMD* Share of patients assigned to >Q12W dosing Assessment done at week 20 > 50 μm CST increase vs avg. OR OR CST over previous 2 scheduled visits ≥ 75 μm CST increase vs lowest CST recorded at OR either of previous 2 scheduled visits 22% macular hemorrhage*, due to nAMD activity Less stringent criteria (post hoc analysis) Treatment change if ALL criteria are met > 25 μm CST increase vs week Presence of new 4% 78% >Q12W Q8W >5 letters BCVA loss vs week 16 BCVA AND 16 CST or new macular hemorrhage 96% . Ph III TENAYA/LUCERNE trial with stringent patient-centric criteria resulted in 22% of patients being allocated to Q8W dosing Using less stringent criteria, only 4% of patients would have been assigned to Q8W dosing (post hoc analysis) 1 Heier et al. Lancet. 2022;399(10326):729-40; TENAYA (NCT03823287) & LUCERNE (NCT03823300); *per the investigator; **Additional patients with a missing Week 20 assessment were considered to have met disease activity criteria and were treated Q8W; Q8W-every 8 weeks; BCVA-best-corrected visual acuity; nAMD-neovascular age-related macular degeneration; CST=central subfield thickness; Note: This analysis is not intended as a cross-trial comparison; This analysis cannot predict whether faricimab-treated patients in TENAYA & LUCERNE would have achieved non-inferiority vs aflibercept 2mg if the treatment regimen had been modified; This analysis is not intended to state or imply long term efficacy or safety 33#34Ophthalmology: Adding new indications Positive Ph III results to be presented at Angiogenesis VABYSMO Vabsymo in RVO Ph III (BALATON/COMINO) susvim o™ Susvimo in DME ranibizumab injection susvimo™ ranibizumab injection Ph III (PAGODA) Week Day 1 4 8 12 16 20 24 28 32 36 40 44 48 52 56 60 64 68 72 Arm A Faricimab 6.0 mg 6x WEEK Q4W followed by PTI Arm B Aflibercept 2.0 mg 6x Q4W followed by faricimab PTI PDS implantation and initial fill Primary Endpoint D1 4 8 12 16 20 24 28 32 36 40 44 48 52 56 60 64 68 72 76 80 84 88 92 96 100 104 112 Roche Susvimo in DR Ph III (PAVILION) Primary Endpoint IR virtual event February 13th MIAMI 16 20 24 28 32 36 40 44 48 52 56 60 64 68 72 76 80 841 88 Angiogenesis Feb 10-11 100 112 X Y Z Final C ○ WEEK D1 4 8 12 Final C Arm A: PDS Q36W, N = 106 ○ ○ OOOOOO Arm A: PDS Q24W, n=381 PDS extension phase Arm B: Monthly ranibizumab, n=253 Primary endpoint at week 24 Core study end at week 72 PDS implantation and initial filla Fixed treatment interval Faricimab PTI Faricimab 6.0 mg Faricimab 6.0 mg PTI/sham Aflibercept 2.0 mg Final study visit O Intravitreal ranibizumab 0.5 mg loading dose Intravitreal ranibizumab 0.5 mg ☐ PDS implantation and initial fill POS refill-exchange ° Patients assessed for supplemental treatment O Visit with no refill-exchange or intravitreal ranibizumab 00 O O O Refill-exchange interval 36 weeks post-implantation Arm B: Control (observation³), N = 68 O O O PDS extension phase Intravitreal ranibizumab 0.5 mg PDS refill-exchange PDS implantation and initial fillb ○ Visit with no refill-exchange or intravitreal ranibizumab Primary endpoint Change from baseline in BCVA at week 24 Primary endpoint BCVA score change from baseline averaged over weeks 60 and 64 as measured via ETDRS chart Primary endpoint Percentage of patients with a ≥2- step improvement from baseline on the ETDRS-DRSS at week 52 • All studies met their respective primary endpoints; safety profiles were consistent with previous trials • Results to be presented at the Angiogenesis virtual medical meeting (Feb 10-11) • IR virtual event planned for Feb 13th (4:30-5:30pm CET/7:30 - 8:30am PST); clinical results to be presented by Veeral Sheth, MD (retinal specialist and clinical investigator) (B/C)RVO=(branch/central) retinal vein occlusion; BCVA-best-corrected visual acuity; HRVO=hemiretinal vein occlusion; CST=central subfield thickness; PTI=personalized treatment interval; QXW-every X weeks; PDS=port delivery system; DME=diabetic macular edema; nAMD=neovascular age-related macular degeneration; DR-diabetic retinopathy; EDTRS(-DRSS)-early treatment diabetic retinopathy study (-diabetic retinopathy severity scale); Eylea (aflibercept) is a registered trademark/product of Regeneron 34 4#352023: Key late-stage news flow* Regulatory Phase III / pivotal readouts Compound Hemlibra Polivy + R-CHP Vabysmo Tecentriq Glofitamab Xofluza Tecentriq + Avastin Tecentriq + chemo Tecentriq Tecentriq + chemo Tiragolumab + Tecentriq Tiragolumab + Tecentriq + chemo Venclexta + dexamethasone Venclexta + azacitidine Alecensa Phesgo OBI (on body injector) Crovalimab Glofitamab + GemOx Lunsumio + Polivy Delandistrogene moxeparvovec (SRP-9001) Ocrevus 6m SC Indication Moderate hemophilia A 1L DLBCL RVO Subcutaneous administration 3L+ DLBCL Influenza (paediatric 1+ yrs.) Adjuvant HCC Neoadjuvant/adjuvant TNBC Adjuvant SCCHN Adjuvant TNBC 1L PDL 1+ NSCLC 1L esophageal cancer t(11;14) R/R MM 1L high risk MDS Adjuvant ALK+ NSCLC HER2+ BC PNH 2L+ DLBCL Milestone EU approval US approval US approval/EU filing US approval/EU filing US/EU approval EU approval Ph III IMbrave050 Ph III GeparDouze/NSABP B-59 Ph III IMvoke010 Ph III IMpassion030 Ph III SKYSCRAPER-01 Ph III SKYSCRAPER-08 (China only) Ph III CANOVA Ph III VERONA Ph III ALINA Ph I (pivotal) Ph III COMMODORE 1/2 Ph III STARGLO Ph III SUNMO** Ph III EMBARK Ph III OCARINA II 2L+ DLBCL DMD RMS/PPMS Stroke patients 4.5-24h Ph III TIMELESS DME Ph III PAGODA TNKase Susvimo Susvimo DR Xolair Food allergy Outcome studies are event-driven: timelines may change; i ** Results are event-driven; read-outs expected in 2023/24 Ph III PAVILION Ph III OUTMATCH Roche 35#36Diagnostics Division Matt Sause CEO Roche Diagnostics Roche#372022: Diagnostics Division sales Sales increase of +3% driven by base business offsetting COVID-19 testing decline Roche 2022 2021 Change in % CHFM CHFM CHF CER Diagnostics Division 17,730 17,760 0 3 Core Lab1 7,775 7,560 3 6 Point of Care¹ 3,589 3,134 15 17 Molecular Lab¹ 3,450 4,174 -17 -15 Diabetes Care 1,598 1,690 -5 -2 Pathology Lab 1,318 1,202 10 11 CER-Constant Exchange Rates; underlying growth of Core Lab excluding Roche Information Solutions: +6%; 1 Sales in the Point of Care customer area include sales from the Liat business (POC molecular), and sales in the Core Lab customer area include sales from the Life Science Alliances, both previously shown as part of Molecular Lab customer area. The comparative information for 2021 has been updated accordingly. In Q1 21 POC molecular sales = 90mCHF, Q2 21=92mCHF, Q3 21=175mCHF, Q4 21-194mCHF. In Q1 21 LS Alliances = 21mCHF, Q2 21-23mCHF, Q3 21-23m CHF, Q4 21=20mCHF. 37#382022: Diagnostics Division highlights Strong growth despite a high base in 2021 CHFbn YoY CER growth Core Lab 1,3 Point of Care³ Molecular Lab³ Diabetes Care Pathology Lab +11% 0.0 2.0 -2% 4.0 +17% -15% +6% · Immunodiagnostics (+7%) • Clinical Chemistry (+9%) • Custom biotech (-7%) • POC Immunodiagnostics (+22%) POC Molecular³ (+22%) • Virology (-20%) • . qPCR&NAP (-31%) • Blood glucose monitoring (-3%) • ⚫ Insulin delivery systems (+5%) • Advanced staining (+9%) EMEA² Asia-Pacific North America Latin America • Companion diagnostics (+25%) 6.0 8.0 CER-Constant Exchange Rates; POC-point of care; 1 Underlying growth of Core Lab excluding Roche Information Solutions: +6%; 2 EMEA-Europe, Middle East and Africa; 3 Sales in Point of Care customer area include sales from the Liat business (POC molecular), and sales in the Core Lab customer area include sales from the Life Science Alliances, both previously shown as part of Molecular Lab customer area. The comparative information for 2021 has been updated accordingly. In Q1 21 POC molecular sales = 90mCHF, Q2 21=92mCHF, Q3 21=175mCHF, Q4 21=194mCHF. In Q1 21 LS Alliances = 21mCHF, Q2 21-23mCHF, Q3 21-23mCHF, Q4 21=20mCHF. 38 30 Roche#392022: Diagnostics Division regional sales Strong base business growth across all regions North America +13% ~29% of divisional sales EMEA1 -16% ~33% of divisional sales Latin America -1% ~6% of divisional sales Growth rates at CER (Constant exchange Rates); 1 Europe, Middle East and Africa Asia Pacific +23% ~32% of divisional sales 50 39 Roche#40Diagnostics Division sales growth by quarter Strong base business growth Diagnostics Division sales growth 55% -Base business sales growth' 48% Roche 28% 31% 24% 18% 17% 18% 9% 10% 7% 8% 5% 2% 1% -2% -5% 3% 11% 8% -4% 0% -9% -17% Q1 20 Q2 20 Q3 20 Q4 20 Q1 21 Q2 21 Q3 21 Q4 21 Q1 22 Q2 22 Q3 22 Q4 22 0.1bn 0.6bn 0.6bn 1.1bn 1.2bn 1.3bn 1.0bn 1.2bn 1.9bn 1.2bn 0.6bn 0.5bn COVID-19 sales Growth rates and absolute values at CER (Constant exchange Rates); 1 Quarterly sales growth excluding COVID-19 sales 40 40#412022: Diagnostics Division Core operating profit decline of -5% Roche 2022 CHFm % sales 2022 vs. 2021 CER growth Sales 17,730 100.0 3% Royalties & other op. inc. 68 0.4 -13% Cost of sales -8,813 -49.7 4% M & D -2,889 -16.3 1% R & D -1,957 -11.0 12% G&A -583 -3.3 10% Admin +4% Core operating profit 3,556 20.1 -5% -9% in CHF CER=Constant Exchange Rates 41 44#42New system launches in US Enabling comparable results in different size laboratories Throughput cobas pure cobas pro✓ cobas pro (high throughput) Serum Work Area solutions US Launch¹ cobas® 5800 cobas® 6800 cobas 8800 ✓ Molecular solutions US Launch2 1 Launched in Q3 2022; 2 Launched in Q4 2022 Roche Increasing access Family concept addressing needs of all lab sizes. Beyond US, will increase access in low and middle income countries Reducing cost Automation and tailored throughput help laboratories and health care systems More sustainable Up to 80% less plastic waste per test 42 42#43FDA emergency use authorization for the mpox assay Running on cobas® 6800/8800 high throughput platforms Roche Throughput cobas® 6800 cobasⓇ 8800 EUA: Emergency Use Authorization Mpox assay NEW · · May 2022: Launch of LightMixⓇ modular virus kits for the detection of the mpox virus (on LightCycler instruments) November 2022: Received FDA EUA for the mpox assay run on cobas 6800/8800 within two months of regulatory pathway opening in September Roche fast response to the public health emergency contributed to fortifying its position and reputation in addressing outbreaks 43#44Roche STRONG-HF1 trial stopped early due to superior efficacy² Significant reduction of hospitalizations or mortality in heart failure Evaluate the efficacy and safety of rapid up-titration of oral HF therapy, supported by Disease burden > 64m patients diagnosed with heart failure annually5 NT-proBNP monitoring2,3,4 >50% mortality after 5 years of patients under current site of care treatment regimen STRONG-HF CONTEMPORARY POST-DISCHARGE MANAGEMENT IN HEART FAILURE Study set up FQ American Heart Association. 6 tests per patient of NT-proBNP are needed for safety monitoring (on label) Serial measurements of NT-proBNP during uptitration of 4 evidence based HF drugs? N=1078 Pts8, 10EP: composite all-cause death + HF hospitalization at day 180 Outcome: 34% decrease in hospitalization and deaths, p<0.05 (NNT=12)2,9 1 Safety, Tolerability and Efficacy of Rapid Optimization, Helped by NT-proBNP testing, of Heart Failure Therapies; 2 Mebazza-A et al. Lancet 2022. 400:1938-1952; 3 Kimmoun-A et al. Eur J Heart Fail 2019. 21: 1459-1467; 4 Gotter-G et 44 al. Eur J Heart Fail 2021. 23:1981-1982; 5 Groenewegen-A et al. Eur J Heart Fail 2020. 22:1342-1356; 'multicenter, randomized, parallel group strategy-based trial; 7 Source: https://clinicaltrials.gov/ct2/show/NCT03412201, Drugs: beta-blockers; angiotensin converting enzyme inhibitors (ACEI), angiotensin receptor blocker (ARB) or angiotensin receptor neprolysin inhibitor (ARNI); and mineralocorticoid receptor antagonist (MRAs); 8 Initially planned study setup of n=1,800 which wasn't reached due to termination for superior efficacy; 9 NNT = Number Needed to Treat#45Roche ElecsysⓇ Amyloid Plasma Panel clinical results Received FDA approval for Elecsys Ⓡ CSF AD assays pTau/Abeta 42 1 Triage Patients undergoing initial evaluation for non-specific cognitive decline1 Elecsys Amyloid Plasma Panel² pTau 181+APOE4 sensitivity>85% specificity > 65% FDA BDD 2 Confirmation Patients referred for amyloid confirmatory testing³ Elecsys CSF AD assays pTau/Abeta 42 sensitivity >90% specificity >90% FDA 3 Therapy Patients identified for future therapies Anti-amyloid antibodies AD patients 吧吧吧 EOE 吧吧吧 Eo ° O 2 3 H = 10 patients 1 Assumed prevalence of AD 30% in symptomatic patients; 2 Mean of clinical performance data from retrospective cohorts measured with Elecsys Amyloid Plasma Panel; Blennow K et al. Clinical performance and robustness of blood-based biomarkers for early detection of amyloid pathology associated with Alzheimer's disease. Alzheimer's Dement. 2022, 18(6):e069052 ³ Alternative to PET scan 45 Non-AD patients#46Diagnostics key launches 2023 Area Product Roche Description CCM Vertical Core Lab cobas pro integrated solutions Modular transportation system, integrated into the existing cobas connection modules, allowing for overhead sample transportation over different work areas or different floors enabling effective use of lab space Scalable and modular serum work area analyzer for mid to high volume clinical chemistry and immunochemistry testing Markets Global China Instruments Automation Molecular Lab Point of Care Pathology Lab cobas pure integrated solutions LightCycler Pro cobas pulse IDH1 R132H (IDH Glioma) Tests Core Lab IL-6 Neonatal sepsis (claim extension) RUO Amyloid Plasma Assays (pTau181 & ApoE4) RUO Digital Pathology Algorithm: Digital pathology algorithm aiding pathologists in scoring PD-L1 (SP142) breast samples, ensuring a PD-L1 SP142 standardized approach and an adjunctive tool to augment diagnostic confidence for research use only Digital solution providing access to an open library of certified IVD-based clinical algorithms navify Algorithm Suite Menu for navify Algorithm Suite Pathology Lab Digital Solutions Lab Insights cobas infinity lab 3.05 navify Marketplace navify Sample Tracking Certified clinical algorithms for oncology applications such as colon and liver cancers Next-generation lab middleware enabling ecosystem of cloud-based solutions for quality control and instrument maintenance Global Selected markets1 Selected markets1 Global Digital marketplace offering lab customers full range of innovative applications (from Roche and third parties) Selected markets¹ Open digital solution offering sample tracking beyond the lab setting (from IVD-sample creation to lab Selected markets1 reception) to improve testing traceability and quality US US Anti-HEV IgG and Anti-HEV IgM Anti-HEV IgM: Immunoassay aiding in the diagnosis of acute HEV infection in clinical settings; Anti-HEV IgG: Immunoassay aiding in the detection of a recent or past HEV infection and enabling accurate seroprevalence determinations. The two assays expand the hepatitis panel (HAV, HBV, HCV, HEV) on the same analytical platform CE HBeAg Quant Immunoassay aiding in diagnosis, monitoring and predicting treatment response for patients with hepatitis B viral infection CE Only immunoassay available on the market with dedicated claim and supporting evidence aiding in diagnosis CE of sepsis in neonates, with potential to reduce newborn mortality Two qualitative immunoassays measuring the phosphorylated Tau 181 protein and apolipoprotein E4 in human plasma for research use only US Serum work area analyzer for low to mid volume clinical chemistry and immunochemistry testing on a footprint of two square meters Flexible real-time PCR instrument with dual IVD and research mode as well as enhanced system features Handheld device combining professional glucose meter and a digital platform to host digital clinical decision support applications (from Roche and third parties) Neuropathology Immunohistochemistry (IHC) solution supporting the detection of tumor cells with the IDH1 R132H mutation aiding pathologists to render a diagnosis of gliomas China US & CE 1 Selected markets: 14 countries with first releases // CE: European conformity; RUO: Research use only; PCR: Polymerase chain reaction; IVD: In vitro diagnostic; IDH: Isocitrate dehydrogenase; HEV: Hepatitis E virus; HAV: Hepatitis A virus; HBV: Hepatitis B virus; HCV: Hepatitis C virus 46 46#47Finance Alan Hippe Chief Financial Officer Roche#482022 results Focus on cash and balance sheet Outlook New Income Statement Representation in 2023 Roche#492022: Highlights Business Group sales growth of +2% due to strong underlying business in both divisions • Core operating profit up by +3% and Core EPS growth +5% (incl. accretion of 4.8%) Proposal to further increase dividend in Swiss francs Cash flow • Strong Operating Free Cash Flow of CHF 17.7bn, -8% lower due to increased net working capital • Net debt decreased by CHF 2.6bn vs. YE 2021 Net financial results • Core net financial result worsened by -475m driven by higher interest expenses IFRS • Net income -6% driven by higher Intangible Assets impairment, partially offset by lower Intangible Assets amortization Growth rates and variances at CER (Constant exchange Rates) Roche 49 49#502022: Group performance Sales growth of +2%, Core Operating profit up +3%, Core EPS growth of +5% 2022 2021 CHFM CHFM CHF Change in % CER Sales 63,281 62,801 1 2 Core operating profit 22,173 21,897 1 3 as % of sales 35.0 34.9 Core net income 17,530 18,071 -3 -1 as % of sales 27.7 28.8 Core EPS (CHF) 20.30 19.81 2 5 IFRS net income 13,531 14,935 -9 -6 as % of sales 21.4 23.8 Operating free cash flow 17,673 19,411 -9 -8 as % of sales 27.9 30.9 Free cash flow 13.041 15,691 -17 -16 20.6 25.0 as % of sales CER-Constant Exchange Rates Roche 50 50#512022: Pharma and Diagnostics underlying business driving growth CHFM 62'801 +2% at CER Diversification of Roche business +273 +903 +3'356 -801 -1,883 2017 CHF 53.3bn -457 -911 Total COVID-19 sales decline equals roughly 1bn 63'281 AHR Diagnostics Other pharma Ophthalmology 2022 CHF 63.3bn AHR Oncology Immunology Neuroscience 2021 Dia Dia Pharma Ronapreve Actemra base COVID-19 excl. sales business sales Ronapreve, Actemra, AHR sales AHR erosion1 Fx 2022 Infectious diseases Hemophilia A 2022 values in reported CHFm, variances in CERm; 1AHR: Avastin, Herceptin, Rituxan/MabThera sales erosion Roche 51#522022: Group operating performance Core operating profit growth of +3% 2022 CHFM abs. CER 2022 vs. 2021 CER growth Sales 63,281 +1,391 2% Royalties & other op. inc. 3,145 +83 3% Cost of sales -18,075 -204 1% M & D -9,546 -159 2% R & D -14,053 -367 3% G & A -2,579 -4 0% Core operating profit 22,173 +740 3% +1% in CHF CER-Constant Exchange Rates Roche 52 52#532022: Royalties and other operating income Higher income driven by one-time Ultomiris patent settlement gains CHFM 3,049 -611 +116 +713 -122 Royalties and other operating income increased by +3% at CER 3,145 2021 Royalty income Out-licensing Income (incl. Ultomiris) Other operating income incl. Income from disp. of products 2022 Ronapreve profit share income CER Constant Exchange Rates Roche 53#542022: Group Core cost of sales (COS) Increase due to volume growth, partially offset by the base effect of the 2021 incremental production costs for Ronapreve & AT-527 CHFM 18'355 18'141 -613 17'528 +827 COS as % of group sales 28.9% 27.9% Underlying COS increase by +5% vs. +6% volume increase 28.6% COS 2021 Incremental production costs Normalized Underlying COS COS COS growth from 2022 for Ronapreve & 2021 adjusted base AT-527 All at CER=Constant Exchange Rates; COS-Cost of Sales Roche 54#552022: Core operating profit and margin 43.7% 41.2% 42.1% % of sales 36.9% 34.9% 35.0% +1.3%p¹ +0.4%p¹ 22.1% 18.6% 20.1% +3%¹ CHFM 21,536 21,897 22,173 +5%¹ -1.7%p¹ 19,477 18,548 19,172 2020 2021 2022 Roche Group Pharma Division At CER-Constant Exchange Rates -5%¹ 2,564 3,925 3,556 Roche Diagnostics Division 55#562022: Core net financial result Net financial result worsened due to higher interest expenses Roche CHFm -751 • Net financial result worsened by -475m at CER • Interest expenses 1 increased by +79% at CER +37 -36 -46 -269 -149 -1,214 2021 Equity securities Net interest income FX G/L Interest expenses1 Other 2022 CER-Constant Exchange Rates; 1 incl. amortization of debt discount and net gains on interest rate derivatives 56 56#572022: Group Core tax rate Increase in core tax rate mainly due to the relative lower impact from the resolution of tax disputes in 2022 compared to 2021 Roche +0.1%p 17.8% 17.9% 1.5% 3.3% Reduction in the effective tax rate from the resolution of tax disputes Tax rate before resolution of tax disputes (Core 14.5% tax rate) Effective tax rate FY 2021 +1.9%p Effective tax rate as reported 16.4% Effective tax rate FY 2022 57 57#582022: Core EPS development Roche Operations growth and accretion effect from share repurchase are main drivers for higher Core EPS CHF 20.05 +4.8% +4.8 p -1.6 p +3.1 p -1.5 p 2021 Operations 1 Ultomiris patent settl. + base effect 2021: Regeneron Profit Sharing Income² 21.02 Net accretion Novartis share repurchase 3 Other 4 2022 At Constant Exchange Rates (CER); 1 Core operating profit excluding impacts from Ultomiris patent settlement and Profit Sharing Income from Regeneron; 2 Net impact from the Ultomiris patent settlement: gross income, net of income tax and non-controlling interests and Profit Sharing Income from Regeneron, net of tax; ³ Impact of lower number of shares partially offset by increase in interest expense; 4 Other (net) include effects from changes in effective tax rate, gains/losses on equity securities, other financial income and expenses and non-controlling interests 58#592022: Non-core and IFRS income Non-core operating expenses above PY driven by higher impairment of intangible assets, partially offset by lower amortization of intangible assets due to Esbriet 2021 2022 Change in % CHFM CHFM CHFM CHF CER Core operating profit 21,897 22,173 277 +1 +3 Global restructuring plans -1,362 -969 393 Amortisation of intangible assets -1,556 -933 623 Impairment of intangible assets¹ -651 -2,837 -2,186 M&A and alliance transactions -55 20 75 Legal & Environmental² -118 22 140 Total non-core operating items -3,742 -4,697 -955 IFRS Operating profit 18,155 17,476 -680 -4 -1 Total financial result & taxes IFRS net income -3,220 -3,944 -724 14,935 13,531 -1,405 -9 -6 CER = Constant Exchange Rates; IA-intangible assets; 1 incl. goodwill; 2 incl. pension plan settlements Roche 59#602022 results Focus on cash and balance sheet Outlook New Income Statement Representation in 2023 Roche#612022: Group Operating Free Cash Flow OFCF -8% driven by movements in NWC and higher investments in IA Roche CHFM +209 -1,611 +93 -231 -198 19'411 OFCF lower by -8%/+1,540m at CER 2021 OP, net of cash adjustments NWC movement Investments in PP&E Investments in IA CER = Constant Exchange Rates; OP = Operating Profit; NWC: Net Working Capital; PP&E = Property, Plant & Equipment incl. increase of lease liability paid; IA = Intangible Assets 17'673 Foreign 2022 exchange 61#622022: Operating free cash flow and margin OFCF -8% driven by movements in NWC and higher investments in IA Roche 36.9% % of sales 34.6% 30.9% 31.1% 27.9% 25.4% -2.4%p¹ 19.0% -3.1%p¹ 14.4% 11.4% -4.5%p¹ -8%¹ CHFM 19,411 -4%¹ 17,673 16,639 15,753 14,815 13,853 2020 2021 2022 Roche Group 1 At CER=Constant Exchange Rates Pharma Division -21%¹ 3,370 2,561 1,571 Diagnostics Division 62#632022: Group net debt development Net debt lower by CHF +2.6bn vs. year end 2021 CHFbn Free Cash Flow CHF 13.0bn vs. 15.7bn in 2021 -4.6 Taxes -4.1 Treasury -0.5 +17.7 -18.2 -10.5 Dividends paid -15.6 -7.8 Trans. own eq. instr. -1.3 M&A & All. trans. -0.3 Curr. Transl. & Other -1.1 Net debt 31 Dec 2021 Operating Free Cash Flow Non-Operating Free Cash Flow Dividends, M&A and Alliance transactions and other Net debt 31 Dec 2022 Intangible Asset Equity Thereof investments in innovation: 2022 2021 -1.1 -0.9 0.0 M&A -0.3 Total -1.4 -0.3 -2.4 -3.6 63 50 Roche#64Balance sheet 31 December 2022 Equity ratio at 36% (31 Dec 2021:31%) and net debt to assets at 18% (31 Dec 2021: 20%) Roche % change in CER vs CHFbn 31 Dec 2021 92.3 88.2 -2% % change in CER vs 31 Dec 2021 92.3 88.2 -2% Cash and 13.0 9.8 -21% marketable 14% 11% Current securities 38.4 27.2 -27% 22.6 liabilities 24.1 +12% 42% 31% Other 24% 27% current Non- assets current 29.0 +13% liabilities 25.6 33% 27% Net debt/ 56.7 54.3 -2% total assets: Non- 62% 62% Equity 18% current (Net assets) 28.3 32.0 +19% assets 31% 36% CER Constant Exchange Rates 31 Dec 31 Dec 2021 2022 31 Dec 31 Dec 2021 2022 64#652022 results Focus on cash and balance sheet Outlook New Income Statement Representation in 2023 Roche#66Currency impact 2022 CHF / USD +2% +4% +4% +4% 0.94 0.95 0.95 0.92 In 2022 impact¹ is (%p): Roche Q1 HY Sep FY 0.90 0.91 0.91 0.91 YTD 0.92 0.92 0.93 0.94 0.98 0.97 0.97 0.96 0.97 0.99 0.97 0.93 Sales -1 0 -1 -1 T Monthly avg fx rates 2022 Average YTD 2022 Average YTD 2021 CHF / EUR Core operating profit 0 -2 -5% -6% -7% -7% Core EPS 0 -3 1.09 1.09 1.09 1.08 1.04 1.03 1.01 1.00 1.04 1.05 1.02 1.02 1.04 1.03 0.99 0.97 0.96 0.98 0.98 0.99 Monthly avg fx rates 2022 Average YTD 2022 Average YTD 2021 1 On group growth rates 2023 currency impact¹ expected (based on 30 December 2022 FX rates): Around -4%p to -6%p on Sales, Core OP & Core EPS 66#672022: Core EPS Core EPS 2022 of CHF 20.62 is basis for Core EPS outlook 2023 at CER CHF CER Constant Exchange Rates 20.30 +0.32 20.62 Core EPS 2022 as reported 2022 foreign exchange losses: Core EPS impact Core EPS 2022 basis for Outlook Core EPS growth 2023 at CER Roche 67#682023 outlook Group sales growth1 • Low single digit decline Core EPS growth¹ Dividend outlook • 1 At Constant Exchange Rates (CER) Broadly in line with sales decline Further increase dividend in Swiss francs Roche 68#692022 results Focus on cash and balance sheet Outlook New Income Statement Representation in 2023 Roche#70Income Statement Presentation 2023 Improving comparability, reducing complexity, reinforcing alignment Roche Changes in Income Statement presentation · Improve external comparability and simplify messaging by using "Selling, General & Administration" costs, from merging "Marketing & Distribution” and “General & Administration". • Reinforcing alignment with latest developments on Revenue by using "Other revenues", instead of “Royalties and Other Operating Income". Introducing a line "Other operating income/expense" for non-revenue income and expenses that do not fall into the regular functional costs. • Simplify and standardise reporting by removing allocations from Corporate to the Divisions and various reporting lines for functions with global accountability such as informatics, human resources, and finance. Consequences • Sales, Group Operating Profit and EPS metrics are unaffected. • No change to Core Reporting Concept. • Allocation changes will reduce costs allocated to Divisions and increase Divisional margins (around 4.0-5.0 %points). Timeline • Implementation effective 1 January 2023. Comparative 2022 information will be restated. 70#71Changes to income statement presentation (1) As published income statement (core) Roche Revised, prior to Group allocation changes Core basis CHFM 30 June 2022 31 Dec 2022 Core basis Reclassifications FY 2022 [HY 2022] CHFM Sales 32,295 63,281 Sales Royalties & Other Operating Income 1,943 3,145 Other Revenue 612m [338m] Cost of Sales (9,305) (18,075) Cost of Sales Marketing & Distribution (4,459) (9,546) Research & Development (6,628) (14,053) General & Administration Core Operating Profit (1,178) (2,579) 12,668 22,173 184m [77m] 30 June 2022 31 Dec 2022 32,295 63,281 1,605 2,533 (9,305) (18,075) Research & Development (6,628) (14,053) 1 Selling, General & Administration Other Operating Income (Expense) Core Operating Profit (5,714) (12,309) 415 796 12,668 22,173 ① Selling, General & Administration: Merging of M&D and G&A to improve comparability vs. peers 2 Other Operating Income (Expense): Reinforces alignment with latest developments on revenue. OOIE will include non-revenue items currently in ROOI, such as "Income from disposal of product rights", as well as "Gains/losses on divestments", as well as expenses that do not fall into the regular functional costs, such as "Pension -past service costs" and "Impairment of goodwill" (non-core). ③ Rename: Former ROOI to Other Revenue including royalty income, profit share income and other out-licensing income 71#72Changes to income statement presentation (2) Revised, prior to Group allocation changes Restated Roche Core basis CHFM 30 June 2022 31 Dec 2022 Reclassifications FY 2022 [HY 2022] Core basis CHFM 30 June 2022 31 Dec 2022 Sales 32,295 63,281 Sales 32,295 63,281 Royalties & Other Operating Income 1,605 2,533 660m [319m] Other Revenue 1,605 2,533 Cost of Sales Research & Development (9,305) (18,075) 1 Cost of Sales (8,986) (17,415) (6,628) (14,053) Research & Development (6,245) (13,255) Selling, General & Administration (5,714) (12,309) 798m [383m] Selling, General & Administration (6,416) (13,767) Other Operating Income (Expense) 415 796 1,458m [702m] Core Operating Profit 12,668 22,173 Other Operating Income (Expense) Core Operating Profit 415 796 12,668 22,173 ① Cost of Sales: Reclassification of globally managed informatics, human resources and finance to SG&A. 2 Research & Development: Reclassification of globally managed informatics, human resources and finance to SG&A. 72 2#73Removing allocations of Group Functions Increase in Divisional Margins of 4-5 % points, no change in Group Margins CHFM As 30 June 2022 Group Functions As published shift Restated published 31 December 2022 Group Functions shift Restated Core Operating Profit Roche Group 12,668 12,668 22,173 22,173 Pharmaceuticals Division 10,318 971 11,289 19,172 1,959 21,131 Diagnostics Division 2,560 393 2,953 3,556 825 Corporate (210) (1,574) (555) 4,381 (3,339) Core Operating Profit as % of Sales 3rd Roche Group 39.2% 39.2% 35.0% 35.0% Pharmaceuticals Division 46.2% 50.5% 42.1% 46.4% Diagnostics Division 25.7% 29.7% 20.1% 24.7% Roche 73#74Doing now what patients need next#75Roche Group development pipeline Marketed products development programmes Roche Pharma global development programmes Roche Pharma research and early development (PRED) Genentech research and early development (gRED) Spark Pharma sales appendix Diagnostics sales appendix Foreign exchange rates information Roche#76Changes to the development pipeline Q4 2022 update Roche New to phase I New to phase II New to phase III 1 NME: 2 NMES: RG1662 basmisanil - Dup 15q syndrome 6 NMES: RG6209 NME - retinal disease RG6421 TMEM16A potentiator - cystic fibrosis RG6524 NME - solid tumors RG6411 NME - solid tumors CHU anti-HLA-DQ2.5 x gluten peptides - celiac disease CHU RAY 121 - immunology 1 NME (moved from phase III): RG6042 tominersen - Huntington's RG6179 anti-IL-6 - UME RG6330 KRAS G12C - 2L NSCLC New to registration 1 NME (US): RG6026 glofitamab - 3L+ DLBCL 1 AI (US & EU): RG7446 Tecentriq SC - subcutaneous formulation, all approved indications Removed from phase I Removed from phase II 1 NME: 2 NMES: RG7880 efmarodocokin alfa - aGVHD Status as of February 2, 2023 Removed from phase III Approvals RG1450 gantenerumab - prodromal to mild Alzheimer's RG7440 ipatasertib + abiraterone - 1L CRPC 5 Als: RG7446 Tecentriq +chemo - 1L MUC I RG7446 Tecentriq + cabozantinib - 2L NSCLC RG3502 Kadcyla + Tecentriq - 2L+ HER-2+ PD-L1+ MBC RG1450 gantenerumab - preclinical Alzheimer's RG6354 zinpentraxin alfa (PRM-151) - IPF 1 NME (US): RG7828 Lunsumio - 3L+ FL 3 Als (US): RG7446 Tecentriq - ASPS RG1569 Actemra - COVID-19 pneumonia RG7421 Cotellic - histiocytosis 2 Als (EU): RG6152 Xofluza - influenza pediatric RG6013 Hemlibra - moderate hemophilia A 76#77Roche Group development pipeline Phase I (55 NMES + 12 Als) RG6007 HLA-A2-WT1 x CD3 AML RG6026 glofitamab monotherapy + combos RG6058 tiragolumab combos heme tumors heme & solid tumors RG6076 CD19-4-1BBL combos heme tumors RG7802 RG7827 RG7828 CHU cibisatamab + T solid tumors RG6026 glofitamab + chemo FAP-4-1BBL monotherapy + combos Lunsumio monotheraphy + combos glypican-3 x CD3 solid tumors tiragolumab + T heme tumors tiragolumab +T+chemo RG6058 solid tumors tiragolumab + T RG6129 HLA-A2-MAGE-A4 x CD3 solid tumors CHU codrituzumab HCC tiragolumab +T RG6160 RG6171 cevostamab (FcRH5 x CD3) giredestrant (SERD) r/r multiple myeloma CHU CD137 switch antibody solid tumors CHU RAS inhibitor solid tumors solid tumors RG6107 RG6139 crovalimab PD1 x LAG3 Phase II (23 NMES + 8 Als) Roche 1L ctDNA high risk DLBCL NSCLC NSCLC neoadj-adj cervical cancer 1L PD-L1+mSCCHN sickle cell disease solid tumors RG6114 RG6156 inavolisib (mPI3K alpha inh) EGFRvIII x CD3 solid tumors CHU SPYK04 solid tumors RG6180 autogene cevumeran + pembrolizumab glioblastoma SQZ PBMC vaccine solid tumors RG6354 zinpentraxin alfa (PRM-151) RG6180 autogene cevumeran + T solid tumors RG6287 IBD RG6357 SPK-8011 1L melanoma myelofibrosis hemophilia A RG6185 belvarafenib (pan-RAF inh) + Cotellic + T solid tumors RG6315 immunologic disorders RG6358 SPK-8016 hemophilia A with inhibitors to factor VIII RG6189 FAP-CD40 ±T solid tumors RG6341 RG6194 runimotamab (HER2 x CD3) BC RG6421 TMEM16A potentiator asthma cystic fibrosis RG6149 astegolimab (Anti-ST2) COPD RG62995 ASO factor B IgA nephropathy RG6234 forimtamig (GPRC5D x CD3) multiple myeloma RG65363 vixarelimab immunology RG6264 Phesgo OBI RG6279 PD1-IL2v + T RG6286 HER2+ BC solid tumors colorectal cancer RG7828 Lunsumio SLE CHU anti-HLA-DQ2.5 x gluten peptides celiac disease CHU RAY121 immunology RG7854/ RG6346/ RG6084** RG6359 RG1662 ruzotolimod (TLR7 ago[3])/ HBV xalnesiran (siRNA)/ PDL1 LNA SPK-3006 basmisanil Pompe disease Dup 15q syndrome RG6290 MAGE-A4 ImmTAC + T solid tumors RG6006 Abx MCP bacterial infections RG6042 tominersen Huntington's RG6292 CD25 MAb combos heme & solid tumors RG6319 LepB inhibitor complicated urinary tract infection RG6100 semorinemab RG6323 IL15/IL15Ra-Fc + T solid tumors RG6035 BS-CD20 MAb multiple sclerosis RG6102 RG6330 KRAS G12C solid tumors RG6091 rugonersen (UBE3A LNA) Angelman syndrome RG6237 RG6333 CD19 x CD28+ glofitamab RG6344 BRAF inhibitor (3) RG6392 RG6411 RG6433 SHP2i combos RG6440 TGFB (SOF 10) r/r NHL solid tumors oncology solid tumors solid tumors solid tumors RG6163 psychiatric disorders RG6416 trontinemab bepranemab Alzheimer's Alzheimer's latent myostatin + Evrysdi SMA Alzheimer's RG6512 FIXa x FX hemophilia RG6182 RG6237 RG6289 RG6418* RG7637 RG6120 RG6209 latent myostatin neurodegenerative diseases neuromuscular disorders RG7314 balovaptan post-traumatic stress disorder RG7412 crenezumab selnoflast Alzheimer's inflammation RG7816 alogabat (GABA Aa5 PAM) RG7906 ralmitaront - psychiatric disorders RG7935 prasinezumab VEGF-Ang2 DutaFab RG6524 solid tumors RG6312 RG65261 camonsertib solid tumors RG6351 RG65382 P-BCMA-ALLO1 multiple myeloma RG65014 OpRegen RG7446 RG7601 Morpheus platform solid tumors RG7921 Venclexta + azacitidine r/r MDS CHU anti-IL-8 recycling antibody Status as of February 2, 2023 RG-No - Roche/Genentech; CHU - Chugai managed; SQZ - SQZ Biotechnology managed; 'Repare Therapeutics managed; 2Poseida Therapeutics managed; ³Kiniksa Pharmaceuticals managed; 4Lineage Cell Therapeutics managed; 5IONIS managed; T-Tecentriq; BS=Brain Shuttle; OBI-On-Body Delivery System; *also developed in Immunology; **combination platform ASO factor B New Molecular Entity (NME) Oncology/Hematology Immunology Infectious Diseases nAMD retinal disease geographic atrophy retinal disease geographic atrophy RG6179 RG7774 RG62995 anti-IL-6 vicasinabin (CB2 receptor agonist) familial Alzheimer's healthy pts ASD schizophrenia Parkinson's DME DR RVO Additional Indication (Al) endometriosis geographic atrophy Metabolism Neuroscience Ophthalmology Other 77#78Roche Group development pipeline Phase III (8 NMES + 41 Als) Registration US & EU (1 NME + 4 Als) glofitamab Tecentriq SC Roche 3L+ DLBCL all approved indications 1L DLBCL SARS-CoV-2 hospitalised SMA pediatric <2months RG3502 RG6026 Kadcyla + T HER-2+ eBC high-risk RG3648 Xolair food allergy RG6026 glofitamab+chemo 2L+ DLBCL Gazyva lupus nephritis RG7446 tiragolumab +T tiragolumab +T 1L PD-L1+ NSCLC 1L esophageal cancer RG7159 Gazyva membranous nephropathy RG7596 Polivy¹ Gazyva RG6058 tiragolumab +T tiragolumab + T locally advanced esophageal cancer stage III unresectable 1L NSCLC Xofluza RG6152 Xofluza systemic lupus erythematosus influenza, pediatric (0-1 year) influenza direct transmission RG6413+ RG6412 RG7916 Ronapreve² Evrysdi³ tiragolumab + T 1L non-squamous NSCLC Ocrevus higher dose RG1594 crovalimab* RG6107 crovalimab PNH aHUS Ocrevus SC RG3625 TNKase RG6114 RG6171 inavolisib (mPI3K alpha inh) giredestrant (SERD) giredestrant (SERD) 1L HR+ MBC RG6168 Enspryng 1L ER+/HER2-mBC RG6168 Enspryng RMS & PPMS RMS & PPMS stroke myasthenia gravis MOG-AD 2Filed in EU RG6330 giredestrant (SERD) + Phesgo KRAS G12C RG7446 Tecentriq + platinum chemo Tecentriq Tecentriq+cabozantinib T + chemo T + capecitabine or carbo/gem T + paclitaxel T + Avastin Tecentriq T+ lurbinectedin Venclexta Venclexta + azacitidine Lunsumio + lenalidomide RG7601 RG7828 RG7853 Lunsumio + Polivy Alecensa ctDNA+ high-risk MIBC 1L maintenance SCLC r/r MM t(11:14) 1L MDS 2L+ FL 2L+ DLBCL ALK+ NSCLC adj New Molecular Entity (NME) Additional Indication (Al) Oncology/Hematology Immunology Infectious Diseases ER+ BC adj 1L ER+/HER2+ BC 2L NSCLC NSCLC periadj NMIBC, high-risk RG6168 Enspryng autoimmune encephalitis RG6356 delandistrogene moxeparvovec (SRP-9001) DMD RG7845 fenebrutinib RMS 1Approved in EU, filed in US 3Approved in US, filed in EU T=Tecentriq PDS-Port Delivery System with ranibizumab *First filed in China in Q3 2022 RG7845 fenebrutinib PPMS RG6179 anti-IL-6 UME RCC adv SCCHN adj 1L TNBC TNBC adj HCC adj Susvimo (PDS) DME RG6321 Susvimo (PDS) DR Susvimo (PDS) WAMD, 36-week RG7716 Vabysmo (faricimab) Vabysmo (faricimab) BRVO CRVO Metabolism Neuroscience Ophthalmology Other Status as of February 2, 2023 78#79NME submissions and their additional indications Projects in phase II and III Roche RG6026 RG6058 glofitamab + chemo 1L ctDNA+ high risk DLBCL tiragolumab +T 1L PD-L1+ cervical RG6330 KRAS G12 C 2L NSCLC zinpentraxin alfa bepranemab RG6416 Alzheimer's RG6354 (PRM-151) RG7314 balovaptan post-traumatic stress New Molecular Entity (NME) Additional Indication (Al) Oncology/Hematology Immunology Infectious Diseases Metabolism Neuroscience Ophthalmology cancer myelofibrosis disorder tiragolumab + T RG6058 locally adv esophageal Lunsumio (mosun) + RG7828 lenalidomide RG7816 Other cancer RG6058 tiragolumab + T 1L non-sq NSCLC 2L FL Lunsumio (mosun) + alogabat (GABA Aa5 PAM) ASD RG7828 ✓ Indicates submission to health authorities has occurred Unless stated otherwise submissions are planned to occur in US and EU PDS=Port Delivery System with ranibizumab Mosun-mosunetuzumab *First filed in China Polivy 2L+ DLBCL (US) RG7845 fenebrutinib RMS astegolimab RG6058 tiragolumab + T 1L PD-L1+ MSCCHN RG6149 (anti-ST2) RG7845 fenebrutinib PPMS COPD tiragolumab+T+/- 1IONIS managed RG6058 chemo NSCLC neoadj/adj RG62991 ASO factor B IgA nephropathy RG7906 ralmitaront schizophrenia RG7854/ tiragolumab +T RG6058 RG6107 1L PD-L1+ NSCLC crovalimab sickle cell disease RG6346/ RG6084 ruzotolimod (TLR7 ago [3])/ xalnesiran (siRNA)/ PDL1 LNA HBV RG7935 prasinezumab Parkinson's tiragolumab + T RG6058 1L esophageal cancer RG6026 glofitamab+chemo RG6139 2L DLBCL PD1xLAG3 solid tumors RG1662 (CN) basmisanil Dup 15q syndrome RG6179 anti-IL-6 UME RG6107 crovalimab⭑* PNH (EU, US) RG6058 tiragolumab + T Stage III unresectable giredestrant tominersen RG6171 (SERD) RG6042 RG6179 Huntington's anti-IL-6 DME 1L NSCLC 1L ER+/HER2-mBC Susvimo giredestrant RG6321 (PDS) DME (US) RG6107 crovalimab aHUS RG6171 (SERD) RG6100 semorinemab Alzheimer's RG62991 Susvimo inavolisib RG6026 glofitamab 3L+ DLBCL ✓ ER+ BC adj giredestrant (SERD) + RG6321 RG6107 crovalimab* PNH (CN) ✓ RG7716 (PDS) DR (US) Vabysmo (faricimab) BRVO/CRVO RG6114 (mPI3K alpha inh) RG6171 Phesgo RG6102 trontinemab Alzheimer's RG6321 ASO factor B geographic atrophy Susvimo (PDS) 1L HR+ BC 1L ER+/HER2+ BC WAMD, 36-week refill delandistrogene autogene cevumeran RG6356 moxeparvovec (SRP-9001) DMD (EU) RG6180 RG6237 1L melanoma latent myostatin + Evrysdi SMA vicasinabin RG7774 (CB2 receptor agonist) DR 2022 2023 2024 2025 and beyond Status as of February 2, 2023 79#80Al submissions for existing products Projects in phase II and III New Molecular Entity (NME) Additional Indication (Al) Oncology/Hematology Immunology Infectious Diseases Metabolism Neuroscience Ophthalmology Other Roche RG3502 RG6264 Phesgo OBI RG7446 HER2+ BC Tecentriq¹ NSCLC periadj RG7446 Gavreto Tecentriq RG6396 RG7446 Tumor agnostic (US) SCCHN adj RG7446 RG7446 Tecentriq + cabozantinib RCC adv RG1594 Ocrevus SC RMS & PPMS Tecentriq + paclitaxel RG7446 TNBC adj RG7159 RG6413+ Ronapreve** RG7446 RG6412 SARS-CoV-2 hospitalized (EU) ✓ Tecentriq + Avastin HCC adj TNKase Tecentriq RG3625 RG7446 RG7159 stroke ctDNA+ high-risk MIBC Kadcyla + Tecentriq HER-2+ eBC high-risk Tecentriq High-risk NMIBC Tecentriq+ lurbinectedin 1l maintenance SCLC Gazyva Gazyva systemic lupus erythematosus membranous nephropathy Actemra Venclexta RG1569 RG7601 RG3648 COVID-19 pneumonia✓ r/r MM t(11:14) Xolair food allergy RG7601 Venclexta + azacitidine 1L MDS Ocrevus higher dose RG1594 RG7446 Tecentriq SC Tecentriq + capecitabine RG7446 all approved indications ✓ or carbo/gem RG6152 Xofluza direct transmission RG7159 Gazyva lupus nephritis RG6168 RMS & PPMS Enspryng MOG-AD TNBC Xofluza Polivy RG7596 RG7853 1L DLBCL (US)✓ Alecensa ALK+ NSCLC adj RG6152 influenza, pediatric (0-1 year) RG6168 Enspryng myasthenia gravis Enspryng RG6168 autoimmune encephalitis 2022 2023 2024 2025 and beyond Status as of February 2, 2023 ✓ Indicates submission to health authorities has occurred Unless stated otherwise submissions are planned to occur in US and EU 1filing timeline based on data from interim analysis OBI-On-Body Delivery System **Ronapreve (casirivimab+imdevimab also known as REGEN-COV in the US) developed in collaboration with Regeneron Pharmaceuticals 80#81Major pending approvals 2022 US Polivy EU China Evrysdi Evrysdi RG7596 1L DLBCL (US) Filed Aug 2022 Tecentriq SC RG7916 SMA presymptomatic pediatric <2mo RG7916 SMA presymptomatic pediatric <2mo RG6264 Filed Nov 2021 RG6413+ RG7446 all approved indications RG6412 Filed Nov 2022 glofitamab Ronapreve* SARS-CoV-2 hospitalized Filed Jan 2022 glofitamab RG6264 RG6026 3L+ DLBCL RG6026 3L+ DLBCL RG6107 Filed Dec 2022 Filed April 2022 RG1569 Actemra SS-ILD Filed June 2022 Phesgo HER-2+ BC Filed July 2022 crovalimab PNH Filed Aug 2022 glofitamab RG6026 Filed Aug 2022 3L+ DLBCL Filed Dec 2022 Tecentriq SC RG7446 all approved indications Filed Nov 2022 Status as of February 2, 2023 New Molecular Entity (NME) Additional Indication (Al) Oncology/Hematology Immunology Infectious Diseases Japan-Chugai Phesgo HER-2+ BC/CC Filed Sept 2022 Roche Metabolism Neuroscience Ophthalmology Other PDS-Port Delivery System with ranibizumab SC=Subcutaneous *Ronapreve (casirivimab+imdevimab also known as REGEN-COV in the US) developed in collaboration with Regeneron Pharmaceuticals 81#82Major granted approvals 2022 and 2023 YTD US EU China Vabysmo (faricimab) RG7716 DME Jan 2022 RG7596 Vabysmo (faricimab) RG7716 WAMD RG7446 Jan 2022 Polivy 1L DLBCL May 2022 Tecentriq NSCLC adj RG7446 Tecentriq NSCLC adj March 2022 RG1569 Actemra RG1569 RA SC RG7716 Japan-Chugai Actemra COVID-19 pneumonia Jan 2022 Vabysmo (faricimab) DME June 2022 April 2022 Actemra Lunsumio (mosunetuzumab) Rozlytrek March 2022 Vabysmo (faricimab) RG1569 GCA IV RG7828 3L+ FL RG6268 NTRK+ solid tumors RG7716 WAMD Feb 2022 June 2022 July 2022 Evrysdi Vabysmo (faricimab) Rozlytrek March 2022 Perjeta + Herceptin RG7916 SMA presymptomatic pediatric <2mo RG7716 DME RG6268 ROS1+ NSCLC RG1273 May 2022 Sept 2022 Aug 2022 Xofluza Vabysmo (faricimab) Polivy RG6152 influenza pediatric Aug 2022 Cotellic RG7716 WAMD RG7596 1L DLBCL RG7446 Sept 2022 Jan 2023 Xofluza Polivy RG7421 histiocytosis RG6152 influenza pediatric RG7596 r/r DLBCL RG6013 Oct 2022 Tecentriq Jan 2023 Hemlibra Jan 2023 RG7446 ASPS Dec 2022 RG6013 moderate hemophilia A Jan 2023 RG105 Lunsumio (mosunetuzumab) RG7828 3L+ FL RG7596 Dec 2022 RG1569 Actemra COVID-19 pneumonia Dec 2022 RG7159 HER-2+ CRC March 2022 Tecentriq NSCLC adj May 2022 Hemlibra acquired Hemophilia A June 2022 Rituxan NMOSD June 2022 1L DLBCL Aug 2022 Gazyva 1L CLL Dec 2022 Polivy Status as of February 2, 2023 New Molecular Entity (NME) Additional Indication (Al) Oncology/Hematology Immunology Infectious Diseases Metabolism Neuroscience Ophthalmology Other Roche 82#83Doing now what patients need next